N
KNTE

Natixis’s Kinnate Biopharma Inc. Common Stock KNTE Stock Holding History

Natixis’s Portfolio KNTE Stock Details KNTE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-672,500
Closed -$11.9M – 1364
2021
Q4 		$11.9M Buy
+672,500
New +$14.2M 0.04% 346

Other funds holding KNTE

FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Natixis's KNTE Position: Q1 2022 in Review

Natixis sold out of Kinnate Biopharma Inc. Common Stock (KNTE) in Q1 2022, closing a stake of 672,500 shares — an estimated $11.9M sold.

Natixis first reported a position in KNTE in Q4 2021 and held it in 1 quarter. The position peaked at $11.9M in Q4 2021. 76 funds tracked by Wall St. Rank hold KNTE as of Q1 2022.

  • Natixis reported no remaining Kinnate Biopharma Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Natixis sold 672,500 Kinnate Biopharma Inc. Common Stock shares in Q1 2022, an estimated $11.9M.
  • Natixis first reported a position in Kinnate Biopharma Inc. Common Stock in Q4 2021 and held it in 1 quarter.
  • Natixis's Kinnate Biopharma Inc. Common Stock position peaked at $11.9M in Q4 2021.
  • 76 funds tracked by Wall St. Rank held Kinnate Biopharma Inc. Common Stock as of Q1 2022.

Based on Natixis's 13F filing for Q1 2022, filed 13 May 2022.